Trade Janux Therapeutics, Inc. - JANX CFD

Janux Therapeutics, Inc. Company profile

About Janux Therapeutics Inc

Janux Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on its Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. Its focus is on developing a class of T cell engagers (TCEs). It is developing a broad pipeline with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Its pipeline includes PSMA-TRACTr, EGFR-TRACTr and TROP2-TRACTr. The Company's PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. Its EGFR-TRACTr is designed to target EGFR. TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target. The Company is also applying its technology to develop a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and CD28.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Janux Therapeutics Inc revenues increased from $0K to $3.6M. Net loss increased from $6.8M to $32.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing va increase from $3M to $23.2M (expense), General and administrative - Balancing v increase from $1.8M to $6.4M (expense).